Zoll discusses GE/Cardiac Science deal
This article was originally published in The Gray Sheet
While "GE has been in the defibrillation business a few times," Zoll Medical CEO Richard Packer says the firm "never really goes at it with full force" as "they see [defibrillation] as complimentary" to their business, rather than "necessary." The exec's comments, which came June 15 at a Thomas Weisel conference, responded to a question about whether Zoll expected to feel any impact from Cardiac Science's recently inked North American distribution agreement with GE Healthcare for the PowerHeart ECD defibrillator (1"The Gray Sheet" May 9, 2005, p. 25). Zoll manufacturers the LifeVest defibrillator...
You may also be interested in...
Cardiac Science anticipates receiving approval from the Japanese Ministry of Health, Labour & Welfare for a biphasic automated external defibrillator by the end of Q2, the firm says
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.